Effect of elongation factor 1α promoter and SUMF1 over in vitro expression of N-acetylgalactosamine-6-sulfate sulfatase

Molecular Biology Reports

Volumn 36, Issue 7, 2009, Pages 1863-1870

  Alméciga Díaz, Carlos J ^a   Rueda Paramo, Maria A ^a   Espejo, Angela J ^a   Echeverri, Olga Y ^a   Montaño, Adriana ^b   Tomatsu, Shunji ^b   Barrera, Luis A ^a  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CMV; Elongation factor 1 promoter; GALNS; Morquio A; SUMF1

Indexed keywords

CHONDROITIN 6 SULFATE; ELONGATION FACTOR 1ALPHA; KERATAN SULFATE; N ACETYLGALACTOSAMINE 6 SULFATASE; PROTEIN; SULFATASE MODIFYING FACTOR 1; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL STRAIN HEK293; CPG ISLAND; CYTOMEGALOVIRUS; ENHANCER REGION; ENZYME ACTIVITY; ENZYME DEFICIENCY; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; MORQUIO SYNDROME; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN EXPRESSION;

BINDING SITES; CELL LINE; CHONDROITINSULFATASES; COMPUTATIONAL BIOLOGY; CPG ISLANDS; CYTOMEGALOVIRUS; GENE EXPRESSION; HUMANS; PEPTIDE ELONGATION FACTOR 1; PLASMIDS; PROMOTER REGIONS, GENETIC; SP1 TRANSCRIPTION FACTOR; SULFATASES; TRANSFECTION;

CYTOMEGALOVIRUS;

EID: 68149172328     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-008-9392-3     Document Type: Article

References (48)

1. Neufeld E, Muenzer J (2001) The mucopolysaccharidosis. In: Scriver C, Beaudet A, Sly W et al (eds) The metabolic and molecular bases of inherited diseases, vol III. McGraw-Hill, New York, pp 3421-3452
2. AM Montaño S Tomatsu G Gottesman 2007 International Morquio A registry: clinical manifestation and natural course of Morquio A disease J Inherit Metab Dis 30 165 174
3. JL Ashworth S Biswas E Wraith 2006 Mucopolysaccharidoses and the eye Surv Ophthalmol 51 1 17
4. A Vellodi EP Young A Cooper 1997 Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres Arch Dis Child 76 92 99
5. S Tomatsu A Montaño A Ohashi 2007 Enzyme replacement therapy in a murine model of Morquio A syndrome Hum Mol Genet 17 815 824
6. S Tomatsu M Fukuda K Masue 1991 Morquio disease: isolation, characterization and expression of full-length cDNA for human N-acetylgalactosamine-6-sulfate sulfatase Biochem Biophys Res Commun 181 677 683
7. J Bielicki M Fuller X Guo 1995 Expression, purification and characterization of recombinant human N-acetylgalactosamine-6-sulphatase Biochem J 311 333 339
8. S Tomatsu A Montaño M Gutiérrez 2007 Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase Mol Genet Metab 91 69 78
9. M Cosma P Pepe I Annunziata 2003 The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases Cell 113 445 456
10. J Landgrebe T Dierks B Schamidt 2003 The human SUMF1 gene required for posttranslational sulfatase modification, defines a new gene family which is conserved from pro- to eukaryotes Gene 316 47 56
11. S Tomatsu A Montaño T Nishioka 2005 Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A) Hum Mutat 26 500 512
12. A Fraldi A Biffi A Lombarda 2007 SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies Biochem J 403 305 312
13. A Fraldi H Hemsley A Crawley 2007 Functional correction of CNS lesions in MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes Hum Mol Genet 16 2693 2702
14. T Takakusaki S Hisayasu Y Hirai 2005 Coexpression of formylglycine- generating enzyme is essential for synthesis and secretion of functional arylsulfatase A in a mouse model of metachromatic leukodystrophy Hum Gene Ther 16 929 936
15. S Cheng A Smith 2003 Gene therapy progress and prospects: gene therapy of lysosomal storage disorders Gene Ther 10 1275 1281
16. M Ellinwood C Vite M Haskins 2004 Gene therapy for lysosomal storage diseases: the lessons and promise of animal models J Gene Med 6 481 506
17. BL Hodges SH Cheng 2006 Cell and gene-based therapies for the lysosomal storage diseases Curr Gene Ther 6 227 241
18. KP Ponder JR Melniczek L Xu 2002 Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs Proc Natl Acad Sci USA 99 13102 13107
19. T Sferra K Backstrom C Wang 2004 Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse Mol Ther 10 478 491
20. AM Traas P Wang X Ma 2007 Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy Mol Ther 15 1423 1431
21. E Papadakis S Nicklin A Baker 2004 Promoters and control elements: designing expression cassettes for gene therapy Curr Gene Ther 4 89 113
22. P Collas 1998 Modulation of plasmid DNA methylation and expression in zebrafish embryons Nucleic Acids Res 26 4454 4461
23. C Toniatti H Bujard R Cortese 2004 Gene therapy progress and prospects: transcription regulatory systems Gene Ther 11 649 657
24. H Hyun-Jeong P Eun-Sook K Seongman 2004 Long-term enzymatic and phenotypic correction in the phenylcetonuria mouse model by adeno-associated virus vector-mediated gene transfer Pediatr Res 56 278 284
25. S Jung I Han A Limave 2001 Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice Proc Natl Acad Sci USA 98 2676 2681
26. Y Liu L Xu A Henning 2005 Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice Mol Ther 11 35 47
27. J Mount R Herzog M Tillson 2002 Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-direct gene therapy Blood 99 2670 2675
28. H Nakai R Herzog J Hagstrom 1998 Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver Blood 91 4600 4607
29. S Smale 2001 Core promoters: active contributors to combinatorial gene regulation Genes Dev 15 2503 2508
30. D Mcleod J Chariton J Mullins 1994 Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island Genes Dev 8 2282 2292
31. J Butler J Kodonaga 2002 The RNA polymerase II core promoter: a key component in the regulation of gene expression Genes Dev 16 2583 2592
32. M Brandeis D Frank I Keshet 1994 Sp1 elements protect a CpG island from de novo methylation Nature 371 435 438
33. Barrera L (2003) Desarrollo de un modelo de vectores usando virus adenoasociados libre de adenovirus para corregir la deficiencia enzimática en las mucopolisacaridosis. In: Leimpn S (ed) Congreso de Errores innatos del Metabolismo y Pesquisa Neonatal, Abstracts, Iguazú, Argentina, p 32
34. Aubin R, Weinfeild M, Paterson M (1991) Preparation of recombinant plasmid DNA for DNA-mediated gene transfer. In: Murray EJ (ed) Methods in molecular biology: gene transfer and expression protocols, vol 7, 1st edn. The Humana Press, Clifton, pp 3-13
35. Okoyama H, Chen C (1991) Calcium phosphate mediated gene transfer into established cell lines. In: Murray EJ (ed) Methods in molecular biology: gene transfer and expression protocols, vol 7, 1st edn. The Humana Press, Clifton, pp 15-20
36. O vanDiggelen H Zhao W Kleijer 1993 A fluorometric enzyme assay for the diagnosis of Morquio type A Clin Chem Acta 187 131 140
37. V Matys O Kel-Margoulis E Fricke 2006 TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes Nucleic Acids Res 34 D108 D110
38. Y Nakashima S Tomatsu T Hori 1994 Mucopolysaccharidosis IV A: molecular cloning of the human N-acetylgalactosamine-6-sulfatase gene (GALNS) and analysis of the 5′-flanking region Genomics 20 99 104
39. J Wang J Xie H Lu 2007 Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction Proc Natl Acad Sci USA 104 13104 13109
40. J Timpe J Bevington J Casper 2005 Mechanisms of adeno-associated virus genome encapsidation Curr Gene Ther 5 273 284
41. A Brooks R Harkins P Wang 2004 Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle J Gene Med 6 395 404
42. I Kim A Józkowicz P Piedra 2001 Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector Proc Natl Acad Sci USA 98 13282 13287
43. D Roeser A Preusser-Kunze B Scgmidt 2006 A general binding mechanism for all human sulfatases by the formylglycine-generating enzyme Proc Natl Acad Sci USA 103 81 86
44. S Tomatsu M Gutierrez T Nishioka 2005 Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase Hum Mol Genet 14 3321 3335
45. S Tomatsu A Montano P Lopez 2006 Determinant factors of spectrum of missense variants in mucopolysaccharidosis IVA gene Mol Genet Metab 89 139 149
46. R Ogawa G Kagiya T Kodaki 2007 Construction of strong mammalian promoters by random cis-acting element elongation Biotechniques 42 628 632
47. A Sandelin P Carninci B Lenhard 2007 Mammalian RNA polymerase II core promoters: insights from genome-wide studies Nat Rev Genet 8 424 436
48. U Alon 2007 Network motifs: theory and experimental approaches Nat Rev Genet 8 450 461